Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studiesFederica Miglietta, Valentina Guarneri, Costanza De Rossi et al.|European Journal of Cancer|2023Cited by 14
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC).Valentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|Journal of Clinical Oncology|2020Cited by 3
242MO Association of tumor-infiltrating lymphocytes (TILs) with recurrence score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of four prospective multicentric studiesFederica Miglietta, Valentina Guarneri, Maria Vittoria Dieci et al.|Annals of Oncology|2023Cited by 2
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancerValentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|IRIS UNIMORE (University of Modena and Reggio Emilia)|2020Cited by 0